BioSpace News Archive

vTv Therapeutics Inc. announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at the 56th Annual Meeting of the European Association for the Study of Diabetes, held virtually September 21-25, 2020.

Investment in South Linden’s Rosewind community kicks-off the company’s nearly $600 million commitment to address racial inequality

- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif.--( BUSINESS WIRE )-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinica

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced a publication in the peer reviewed, open access journal OncoImmunology of a paper on HB-201,

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, has been awarded a $2 million grant by the Peer Reviewed Orthopedic Research Program (PRORP) of the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (DSMB) has unanimously approved the continuation of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The DSMB is a committee of clinical research experts,

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , announced today that John A. Wagner , M.D., Ph.D., has joined the company as chief medical officer (CMO). Since unveiling in 2019 , Cygnal has deepened its executive and scientific leadership. Dr. Wagner is th

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch to Corza Health, Inc.

7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, has been awarded a two-year, $2 million Small Business Innovation Research grant from the National Cancer Institute of the U.S. National Institutes of Health.

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, and focused on innovative therapeutics for oncology, inflammation and infectious disease, announced plans for demerging its StemPrintER asset into a separate and independently listed public company, Accustem Sciences Limited.